Pablo L. Ortiz‐Romero

Research interests

Publications

• EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023

  European Journal of Cancer · 2023 · 10.1016/j.ejca.2023.113343

• Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain

  The Lancet Infectious Diseases · 2022 · 10.1016/s1473-3099(22)00794-0

• Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)01436-2

• Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

  Blood · 2021 · 10.1182/blood.2021012057

• Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00065-6

• Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state

  Nature Medicine · 2020 · 10.1038/s41591-020-1073-3

• Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30379-6

• The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

  British Journal of Dermatology · 2018 · https://doi.org/10.1111/bjd.17258

• Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine

  Nature · 2017 · 10.1038/nature22977

• Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31266-7

• Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31266-7

• European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017

  European Journal of Cancer · 2017 · https://doi.org/10.1016/j.ejca.2017.02.027

• Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

  Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2017 · 10.1016/j.dadm.2017.04.002

• Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.7142

• PLCG1 mutations in cutaneous T-cell lymphomas

  Blood · 2014 · https://doi.org/10.1182/blood-2013-05-504308

• EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*

  Blood · 2011 · https://doi.org/10.1182/blood-2011-05-351346

• Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.32.0630

• Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells

  Cancer Cell · 2009 · https://doi.org/10.1016/j.ccr.2009.07.004

• Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers

  The American Journal of Surgical Pathology · 2008 · https://doi.org/10.1097/pas.0b013e31818e52fe

• A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis

  Cancer Research · 2007 · https://doi.org/10.1158/0008-5472.can-06-3481

• Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases

  Blood · 2007 · https://doi.org/10.1182/blood-2007-04-087288

• EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

  European Journal of Cancer · 2006 · https://doi.org/10.1016/j.ejca.2006.01.025

• Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome

  JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj103

• Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles

  American Journal Of Pathology · 2004 · https://doi.org/10.1016/s0002-9440(10)63110-0

• Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study

  Blood · 2003 · https://doi.org/10.1182/blood-2002-11-3574

Current projects

No projects listed.